Range of suitable clients: CDEC reviewed the uncertainty in the quantity of individuals with moderately significant to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some people that are categorized as getting moderate or reasonable ailment may have a significant bleeding phenotype, https://hemgenix54780.blogstival.com/57447656/not-known-details-about-hemgenix